Alones Creative
A leading European medical group announced a new framework for treating obesity on Thursday, recommending Novo’s (NVO) semaglutide and Lilly’s (NYSE:LLY) tirzepatide, marketed as Wegovy and Zepbound, respectively, should be first-line options for obesity and associated complications.
The European Association
